ICAM1 and Niemann-Pick disease: Anti-ICAM-1-coated nanocarriers have also been used to target recombinant proteins, such as human acid sphingomyelinase to ICAM-1-positive cells, including activated endothelial cells and Niemann–Pick disease patient fibroblasts.